 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper129th MAINE LEGISLATURE
FIRST REGULAR SESSION-2019
Legislative Document No. 1362
H.P. 984 House of  Representatives, March 21, 2019
An Act  To Fund Opioid Treatment by Establishing an Excise  Tax 
on Manufacturers  of Opioids
Reference to the Committee on Health  and Human Services suggested and  ordered printed.
ROBERT  B. HUNT
Clerk
Presented by Representative O'NEIL  of Saco.
Cosponsored by Senator CHIPMAN of Cumberland  and
Representatives: BAILEY  of Saco, GATTINE  of Westbrook, McCREIGHT of Harpswell, 
PERRY of  Calais, TIPPING of Orono, WARREN of Hallowell, Senators:  GRATWICK  of 
Penobscot, SANBORN, L. of Cumberland.

Page 1 - 129LR1952(01)-11Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  22 MRSA §1511, sub-§2, ¶¶B and C, as enacted by PL 1999, c. 401, Pt. 
3V, §1, are amended to read:
4B.  Money from any other source, whether public or private, designated for deposit 
5into or credited to the fund; and
6C.  Interest earned or other investment income on balances in the fund.; and
7Sec. 2.  22 MRSA §1511, sub-§2, ¶D is enacted to read:
8D.  Proceeds from the tax on opioids under Title 36, section 4921.  Proceeds credited 
9to the fund under this paragraph must be deposited into the Opioid Stewardship Fund 
10under section 1513.
11Sec. 3.  22 MRSA §1511, sub-§6, ¶G, as amended by PL 2017, c. 407, Pt. A, 
12§71, is further amended to read:
13G.  Substance use disorder prevention and treatment; and
14Sec. 4.  22 MRSA §1511, sub-§6, ¶H, as amended by PL 2007, c. 539, Pt. IIII, 
15§3, is further amended to read:
16H.  Comprehensive school health and nutrition programs, including school-based 
17health centers.; and
18Sec. 5.  22 MRSA §1511, sub-§6, ¶I is enacted to read:
19I.  Opioid use disorder prevention, treatment and recovery services funded under 
20section 1513.
21Sec. 6.  22 MRSA §1513 is enacted to read:
22§1513.  Opioid Stewardship Fund
231.  Fund established.  The Opioid Stewardship Fund is established as a restricted 
24account within the fund under section 1511, subsection 11 for the purpose of funding the 
25services under section 1511, subsection 6, paragraph I. The Opioid Stewardship Fund is 
26funded from the tax on opioids collected from all proceeds received under section 1511, 
27subsection 2, paragraph D and appropriations, allocations and contributions from private 
28and public sources.  Any unexpended balances remaining in the Opioid Stewardship Fund 
29at the end of any fiscal year do not lapse and must be carried forward to the next fiscal 
30year.
312.  Report.  By April 1st of each calendar year, a manufacturer subject to the tax 
32under Title 36, section 4921 shall report to the department in a form determined by the 
33department the following information on opioids made by the manufacturer subject to the 
34tax that were distributed in the State the previous calendar year:
35A.  The manufacturer's name, address, telephone number, e-mail address, website 
36address and United States Department of Justice, Drug Enforcement Administration 
Page 2 - 129LR1952(01)-11registration number and any registration or identification number required by an 
2agency of the State;
3B.  The name, address and United States Department of Justice, Drug Enforcement 
4Administration registration number of the person to whom the opioids subject to the 
5tax under Title 36, section 4921 were provided in the State and each date the opioids 
6were provided;
7C.  The gross receipts in dollars of all opioids distributed;
8D.  The name and national drug code of each opioid distributed;
9E.  The number of containers and the metric quantity of controlled substance in each 
10container of opioids distributed;
11F.  The total number of morphine milligram equivalents of opioids that were 
12distributed; and
13G.  Any other information determined necessary by the department.
14The department shall forward the information received under this subsection to the State 
15Tax Assessor for the administration of the tax under Title 36, section 4921.  For purposes 
16of this subsection, "distribution" has the same meaning as in Title 36, section 4921, 
17subsection 1, paragraph B.
183.  Rules.  The department, in consultation with the Maine Board of Pharmacy under 
19Title 32, section 13711, shall adopt rules to carry out the purposes of this section.  Rules 
20adopted under this subsection are routine technical rules as defined in Title 5, chapter 
21375, subchapter 2-A.
22Sec. 7.  36 MRSA c. 723 is enacted to read:
23CHAPTER 723
24TAX ON OPIOIDS
25§4921.  Opioid tax
261.  Definitions.  As used in this chapter, unless the context otherwise indicates, the 
27following terms have the following meanings.
28A.  "Distribution" means the final sale of opioids to a consumer.
29B.  "Manufacturer" means a person that makes opioids.
30C.  "Opiate" means the dried, condensed juice of a poppy, Papaver somniferum L., 
31that has a narcotic, soporific, analgesic and astringent effect.
32D.  "Opioid" means:
33(1)  An opiate;
34(2)  A synthetic or semisynthetic narcotic that has effects similar to natural opium 
35alkaloids but is not derived from opium; or
36(3)  A derivative of an opioid described in subparagraph (1) or (2).
Page 3 - 129LR1952(01)-112.  Tax rate.  Beginning January 1, 2020, an excise tax is imposed upon opioids 
2manufactured by a manufacturer that are distributed in the State at the rate of 0.1¢ per 
3morphine milligram equivalent.
43.  Exemptions.  A person is exempted from the tax under this section:
5A.  If the State is prohibited from taxing the person under the United States 
6Constitution or laws of the United States or under the Constitution of Maine; or
7B.  For opioids distributed in the State for the purpose of medication-assisted 
8treatment of substance use disorder.  The Maine Board of Pharmacy under Title 32, 
9section 13711 periodically shall provide to the assessor a list of medications 
10exempted under this paragraph.
114.  Avoidance.  A manufacturer subject to the provisions of this section may not pass 
12a tax assessed under this section on to a consumer in the State.  A manufacturer that 
13violates this subsection commits a civil violation for which a penalty of not more than 
14$1,000,000 may be adjudged.
155.  Revenue.  All taxes, interest, penalties and other amounts collected from the tax 
16imposed under this section must be deposited into the Fund for a Healthy Maine under 
17Title 22, section 1511, subsection 2, paragraph D.
18Sec. 8.  Manufacturers to report for previous year.  By April 1, 2020, a 
19manufacturer subject to the tax under the Maine Revised Statutes, Title 36, section 4921 
20shall submit a report to the Department of Health and Human Services under Title 22, 
21section 1513, subsection 2 for the calendar year 2019.
22SUMMARY
23This bill establishes the Opioid Stewardship Fund within the Fund for a Healthy 
24Maine for the purpose of supporting opioid use disorder prevention, treatment and 
25recovery funded by an excise tax of 0.1¢ per morphine milligram equivalent assessed 
26against opioid drug manufacturers for opioid drugs purchased by consumers in the State.
